Department of pharmaceutics, I.S.F. College of Pharmacy, Moga, Punjab, India.
National Institute of Animal Biotechnology, Hyderabad, India.
Biomed Pharmacother. 2019 Apr;112:108601. doi: 10.1016/j.biopha.2019.108601. Epub 2019 Feb 16.
Pulmonary route is extensively studied for the diagnosis and treatment of pulmonary and extra pulmonary disease conditions such as asthma, tuberculosis, emphysema, and bronchitis. Formulation design, inhalation device and particle size play key role in determining the aerosol performance. The lack of desired clinical outcome along with the problem regarding efficacy or any adverse drug effect may arise due to improper training and education in use of the device to control the actuation and aerosol inhalation. This review summarizes the difference in the mechanistic features of current marketed aerosol delivery devices with respect to mechanism of aerosol generation with possible advancements in the aerosol design. The delivery options in the pulmonary route and its merits together with the limitations are also discussed. An update is provided regarding the current research and clinical outcome of the use of inhalational technology.
肺部给药途径广泛用于肺部和肺外疾病的诊断和治疗，例如哮喘、肺结核、肺气肿和支气管炎。制剂设计、吸入装置和粒径在决定气溶胶性能方面起着关键作用。由于对设备的使用控制启动和气溶胶吸入方面的培训和教育不当，可能会出现缺乏所需临床结果以及疗效或任何药物不良反应的问题。这篇综述总结了目前市售气溶胶递送装置在气溶胶生成机制方面的机械特征差异，以及在气溶胶设计方面的可能进展。还讨论了肺部给药途径的给药选择及其优点以及局限性。提供了关于吸入技术使用的当前研究和临床结果的最新信息。
